Updates are available Correction dated 2021-02-23

Article History

Received: 27 July 2020

Accepted: 21 September 2020

First Online: 8 October 2020

Change Date: 23 February 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s13045-020-01023-9

Ethics approval and consent to participate

: All patients had signed an informed consent form approved by the Institutional Review Board (IRB). Data were collected under MDACC protocols DR09-0223 and PA12-0395 for patients with <i>FLT3-</i>mutated AML.

: Not applicable.

: ND has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, and Agios. GB reports personal fees from FTC Therapeutics, personal fees from Argenx, personal fees from PTC Therapeutics, personal fees from BioLine Rx, personal fees from BioTheryX, personal fees from Nkarta, Inc., personal fees from Treadwell Therapeutics. JC reports grants and personal fees from Daiichi, grants and personal fees from Novartis, grants and personal fees from Pfizer, grants from Astellas, grants from Arog. CD reports personal fees from AbbVie, personal fees from Agios, personal fees from Novartis, personal fees from ImmuneOnc, personal fees from Daiichi Sankyo, personal fees from Celgene, personal fees from Takeda, personal fees from Notable Labs. GI reports grants and personal fees from Novartis, grants from Syndax, grants from Celgene. TK reports personal fees from Novartis, grants and personal fees from Pfizer, grants from BMS, grants and personal fees from AbbVie, grants and personal fees from Genentech, grants and personal fees from JAZZ, grants from Amgen, grants from AZeneca. HK reports grants and other from AbbVie, grants and other from Agios, grants and other from Amgen, grants from Ariad, grants from Astex, grants from BMS, from Cyclacel, grants from Daiichi Sankyo, grants and other from ImmunoGen, grants from Jazz Pharma, grants from Novartis, grants and other from Pfizer, other from Actinium, other from Takeda. MK reports grants and personal fees from AbbVie, grants and personal fees from Genentech, grants and personal fees from F. Hoffman La Roche, grants and personal fees from Stemline Therapeutics, personal fees from Amgen, grants and personal fees from Forty -Seven, grants and personal fees from Kisoji, grants from Eli Lilly, grants from Cellectis, grants from Calithera, grants from Ablynx, grants from Agios, grants from Ascentage, grants from Astra Zeneca, grants from Kisoji, personal fees from Reata Pharmaceutical. In addition, MK has a patent US 7,795,305 B2 with royalties paid to Reata Pharma, a patent 62/993,166 issued to Eli Lilly, and a patent TBD pending to Novartis. KP reports personal fees from Astellas Pharma. NP Dr. Pemmaraju reports personal fees from Pacylex Pharmaceuticals, grants and other from Affymetrix, grants from SagerStrong Foundation, personal fees from Incyte, personal fees and other from Novartis, personal fees from LFB Biotechnologies, personal fees, non-financial support and other from Stemline Therapeutics, personal fees and non-financial support from Celgene, personal fees, non-financial support and other from AbbVie, personal fees and non-financial support from MustangBio, personal fees from Roche Diagnostics, personal fees from Blueprint Medicines, personal fees and non-financial support from DAVA Oncology, other from Samus Therapeutics, other from Cellectis, other from Daiichi Sankyo, other from Plexxikon. FR reports personal fees and other from Astellas, personal fees from Daiichi, other from Novartis. NS reports grants from Astellas, personal fees from Amgen, personal fees from AstraZeneca, grants and personal fees from Takeda Oncology. KT reports personal fees from Symbio Pharmaceuticals, Novartis, Celgene, GSK, personal fees from DAVA Oncology. MY reports grants from Daiichi Sankyo, Inc., grants from Pfizer. Rest of the authors reported no conflict of interest.